Edition:
United States

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.88USD
13 Jul 2018
Change (% chg)

$0.16 (+5.88%)
Prev Close
$2.72
Open
$2.77
Day's High
$2.89
Day's Low
$2.69
Volume
52,608
Avg. Vol
41,580
52-wk High
$3.30
52-wk Low
$1.00

Chart for

About

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary... (more)

Overall

Beta: --
Market Cap(Mil.): $55.04
Shares Outstanding(Mil.): 35.51
Dividend: --
Yield (%): --

Financials

  BLPH.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -1.39 -- --
ROI: -187.88 2.29 14.61
ROE: -359.90 3.86 16.34

BRIEF-Bellerophon Therapeutics Q1 Shr Loss $0.04

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 10 2018

BRIEF-Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse

* BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

May 08 2018

BRIEF-Bellerophon Q4 Loss Per Share $0.44

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Bellerophon Says Over 100 Patients In Late-Stage Study Testing Inopulse For Treatment Of High Blood Pressure

* BELLEROPHON THERAPEUTICS ANNOUNCES ENROLLMENT EXCEEDS 100 PATIENTS IN PHASE 3 INOVATION-1 STUDY EVALUATING INOPULSE® FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

Jan 29 2018

Earnings vs. Estimates